A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine
| Autor: | Abdullah M Al Alawi, Hatem Farhan, Masoud Kashoub, Bader Al Rawahi, Juhaina Salim Al-Maqbali, Asaad Mohammed Al Hinaai, Sara Al Rasbi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty COVID-19 Vaccines Deep vein Pandemic medicine Humans RNA Messenger Pandemics BNT162 Vaccine Venous Thrombosis Rivaroxaban Vaccines business.industry SARS-CoV-2 COVID-19 General Medicine Emergency department Articles Middle Aged medicine.disease Thrombosis Pulmonary embolism Vaccination Venous thrombosis medicine.anatomical_structure Female business Pulmonary Embolism COVID-19 vaccine medicine.drug |
| Zdroj: | The American Journal of Case Reports |
| ISSN: | 1941-5923 |
| Popis: | Patient: Female, 59-year-old Final Diagnosis: Deep vein thrombosis • pulmonary embolism • thrombosis Symptoms: Chest pain • shortness of breath Medication: — Clinical Procedure: — Specialty: Hematology • Infectious Diseases • General and Internal Medicine Objective: Unusual clinical course Background: The COVID-19 pandemic is an ongoing cause of the current global healthcare crisis. Several vaccines were approved for use by emergency vaccination campaigns worldwide. At present, there are very few reports of COVID-19 vaccine-induced immune-thrombotic thrombocytopenia, a variant of heparin-induced thrombocytopenia (HIT), in comparison to the massive number of vaccinated people worldwide. Case Report: A 59-year-old woman presented to the Emergency Department with a 3-day history of sudden-onset left leg pain 7 days after receiving her first dose of BNT162b2 mRNA COVID-19 (Pfizer-BioNTech). She was diagnosed with deep vein thrombosis (DVT) and pulmonary embolism (PE) and found to have a positive HIT screen with optical density (OD) of 0.6 via ELISA test. She was hospitalized for 4 days and discharged home with an oral anticoagulant (rivaroxaban). Conclusions: This case report describes a possible link between BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccination and thromboembolism. However, further data are needed to support such an association. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|